NBCC responds to ODAC vote on Avastin® news-research May 25, 2022 NBCC made the case in 2008 that accelerated approval for bevacizumab (Avastin®) was lowering the bar on drug approval. There Read More
Hello world! Uncategorized May 16, 2022 Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Read More